Biosensors to Participate in the Transcatheter Cardiovascular Therapeutics Symposium 2006

Oct 21, 2006, 01:00 ET from Biosensors International Group, Ltd.

    SINGAPORE, Oct. 21 /Xinhua-PRNewswire/ -- Biosensors International
 Group, Ltd., ("Biosensors" or the "Company", Bloomberg: BIG SP) is pleased
 to announce that it will be participating in the Cardiovascular Research
 Foundation's eighteenth annual Transcatheter Cardiovascular Therapeutics
 ("TCT") scientific symposium, which is being held from 22 - 27 October 2006
 in Washington D.C. Biosensors will occupy booth #1450 at the Washington
 Convention Center.
     Below is a schedule of major events for Biosensors at TCT (all times
 are in U.S. Eastern Daylight Time):
     Tuesday, Oct. 24
      -- Breakfast Meeting: 7- 8 a.m.; Washington Convention Center; Room 150B.
         "The New Generation of Drug-Eluting Stents - Will they Meet the
         Clinical Need?" Moderated by Dr. David Holmes, Jr., Mayo Clinic,
         Rochester. This breakfast meeting, sponsored by Biosensors and its
         partner Xtent Inc., will offer a comprehensive look at the safety
         issues of polymer on drug-eluting stents and how the two companies'
         drug-eluting stent technologies fit into this safety landscape.
         Speakers include: Dr. Renu Virmani, CVPath, Gaithersburg; Dr. Miodrag
         Ostojic, Clinical Center of Serbia, Belgrade, Serbia; and Dr. Stephan
         Windecker, Swiss Cardiovascular Center Bern, Bern, Switzerland. The
         meeting will be available via webcast at Biosensors' corporate website
     Thursday, Oct. 26
      -- Scientific Symposia: The Drug-Eluting Stent Summit 2006: 2:00-3:50
         p.m.; Washington Convention Center, Ballroom C, Level 3. Dr. David
         Holmes, Jr. will present on Biosensors' BioMatrix(R) Biolimus-eluting
         stent clinical programs - STEALTH, BEACON and LEADERS trials. Dr.
         Thomas Ischinger will also present results and outcomes from
         Biosensors' EAGLE study.
     Biosensors' technology will also be presented through its partners
 Terumo Corporation, Xtent Inc., and Devax Inc. A schedule of the major
 events for Biosensors' partners during TCT is as follows:
     Tuesday, Oct. 24
      -- NOBORI 1 clinical trial results: 12.45 p.m.; Washington Convention
         Center, Main Arena. Dr. Bernard Chevalier will present the nine-month
         clinical and angiographic follow-up results of Terumo's NOBORI 1
         clinical trial. NOBORI 1 is a prospective, randomized trial of
         Biolimus A9(R) and Paclitaxel-eluting stents.
     Wednesday, Oct. 25
      -- Scientific Presentations:
         Coronary Stent Design and New Clinical Trial Insights (Washington
         Convention Center, Room 145AB)
         -- 9.45 a.m.   Dr. Charles Simonton will present on Xtent Inc.'s novel
                        modular design for customized stenting
         -- 11.35 a.m.  Dr. Fausto Feres will present on Devax Inc.'s Axxess
                        and Axxess Plus stents
         -- 11.59 a.m.  Dr. Akiyoshi Miyazawa et al. will present on the
                        intravascular ultrasound results of the Devax Inc.'s
                        Axxess Plus stent.
     Thursday, Oct. 26
     Scientific Symposia: The Drug-Eluting Stent Summit 2006 (Washington
 Convention Center, Ballroom C, Level 3)
         -- 2.15 p.m.  Dr. Bernard Chevalier will present data on Terumo's
                       NOBORI Biolimus-eluting stent clinical trials
         -- 2.25 p.m.  Dr. Stefan Verheye will present Devax's multi-center
                       registry results and outcomes of its Axxess self-
                       expanding bifurcation Biolimus-eluting stent in the left
                       main subset
         -- 2.35 p.m.  Prof. Eberhard Grube will present on Xtent's CUSTOM
                       modular Biolimus-eluting stent.
     Media Contact
     Biosensors International Group
     Ms Tina Lim, Executive, Corporate Communications
     Tel: (65) 6213 5712
     Media Relations / Investor Relations Firm
     United States
     Allen & Caron Inc.
     Mr. Matt Clawson
     Executive Vice President, Investor Relations
     Tel: (1) 949 474 4300
     About Biosensors International Group, Ltd.
     Biosensors develops, manufactures and markets innovative medical
 devices used in interventional cardiology and critical care procedures.
 Biosensors is well-positioned to emerge as a leader in drug-eluting stents,
 an evolving therapy that is rapidly gaining market share from traditional
 therapies such as bare-metal stenting and open-heart surgery. Biosensors
 has internally developed technology to address each component of a
 drug-eluting stent system, including a stent, a stent delivery catheter, a
 biodegradable polymer and a proprietary anti-restenotic drug. It is
 pursuing two separate drug-eluting stent programs, BioMatrix(R) and
 Axxion(TM), and has licensed aspects of its drug-eluting stent technology
 to four companies.
     Forward Looking Statements
     Certain statements herein include forward-looking statements within the
 meaning of the U.S. Private Securities Litigation Reform Act of 1995.
 Forward- looking statements generally can be identified by the use of
 forward-looking terminology, such as "may," "will," "expect," "intend,"
 "estimate," "anticipate," "believe," "project" or "continue" or the
 negative thereof or other similar words. All forward-looking statements
 involve risks and uncertainties, including, but not limited to, customer
 acceptance and market share gains, competition from companies that have
 greater financial resources; introduction of new products into the
 marketplace by competitors; successful product development; dependence on
 significant customers; the ability to recruit and retain quality employees
 as Biosensors grows; and economic and political conditions globally. Actual
 results may differ materially from those discussed in, or implied by, the
 forward-looking statements. The forward- looking statements speak only as
 of the date of this release and Biosensors assumes no duty to update them
 to reflect new, changing or unanticipated events or circumstances.

SOURCE Biosensors International Group, Ltd.